Ratings Thermo Fisher Scientific

Equities

TMO

US8835561023

Market Closed - Nyse Other stock markets 04:00:01 2023-12-05 pm EST			5-day change	1st Jan Change
491.6 ^USD	-0.76%		+1.17%	-10.73%

Dec. 01	Thermo Fisher Scientific Unit Extends Expiration of Tender Offer for Olink Shares, ADS	MT
Dec. 01	Thermo Fisher Scientific and Project Hope Partner to Advance Health Equity Among HIV Positive Youth in Sub-Saharan Africa	CI

Summary

According to Refinitiv, the company's ESG score for its industry is good.

Strengths

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The company returns high margins, thereby supporting business profitability.
Analysts covering this company mostly recommend stock overweighting or purchase.
The opinion of analysts covering the stock has improved over the past four months.
Considering the small differences between the analysts' various estimates, the group's business visibility is good.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
The group shows a rather high level of debt in proportion to its EBITDA.
With an expected P/E ratio at 31.33 and 28.47 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
The company's "enterprise value to sales" ratio is among the highest in the world.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The company is highly valued given the cash flows generated by its activity.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last few months, analysts have been revising downwards their earnings forecast.
Over the past four months, analysts' average price target has been revised downwards significantly.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector : Advanced Medical Equipment & Technology

	1st Jan change	Capi.	ESG Refinitiv
THERMO FISHER SCIENTIFIC	-10.73%	191 B $	B
DANAHER CORPORATION	-17.32%	164 B $	B-
INTUITIVE SURGICAL, INC.	+16.65%	110 B $	B-
SIEMENS HEALTHINEERS AG	+12.35%	63 269 M $	A-
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-8.59%	49 770 M $	B+
EDWARDS LIFESCIENCES CORPORATION	-7.72%	41 958 M $	B+
AGILENT TECHNOLOGIES, INC.	-14.55%	37 649 M $	A
GE HEALTHCARE TECHNOLOGIES INC.	+16.39%	31 580 M $	-
RESMED, INC.	-22.67%	23 760 M $	B+
PHILIPS NV	+37.87%	18 649 M $	B

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes